Brief: Acumen Pharmaceuticals To Present Deeper Insights From First-In-Human Phase 1 Study Of Acu193 For Early Alzheimer's
04/10/2023 13:06
Oct 4 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O :
* ACUMEN PHARMACEUTICALS TO PRESENT DEEPER INSIGHTS FROM
FIRST-IN-HUMAN PHASE 1 STUDY OF ACU193 FOR EARLY ALZHEIMER’S
DURING SYMPOSIUM AT THE 16TH ANNUAL CLINICAL TRIALS ON
ALZHEIMER’S DISEASE (CTAD)
Source text for Eikon: ID:nGNX9l5xdM
Further company coverage: ABOS.O
((Reuters.Briefs@thomsonreuters.com;))